Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Has $5.95 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX)

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 39,111 shares of the pharmaceutical company’s stock after buying an additional 1,578 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Vertex Pharmaceuticals were worth $5,945,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in VRTX. Smithfield Trust Co. acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth $135,000. FNY Managed Accounts LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth $162,000. Baldwin Brothers Inc. MA acquired a new stake in Vertex Pharmaceuticals during the 4th quarter worth $184,000. SeaCrest Wealth Management LLC acquired a new stake in Vertex Pharmaceuticals during the 4th quarter worth $184,000. Finally, Fuller & Thaler Asset Management Inc. acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth $198,000. 92.81% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have commented on VRTX. Barclays lifted their target price on shares of Vertex Pharmaceuticals from $180.00 to $200.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. HC Wainwright reaffirmed a “hold” rating and set a $103.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, February 1st. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, January 21st. Robert W. Baird reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Finally, Citigroup reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Thursday, February 1st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and twenty-five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $180.07.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $151.60 on Friday. The firm has a market cap of $39,423.89, a price-to-earnings ratio of 145.77, a P/E/G ratio of 2.27 and a beta of 1.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.79 and a quick ratio of 4.58. Vertex Pharmaceuticals Incorporated has a one year low of $84.39 and a one year high of $174.96.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.08. The firm had revenue of $651.63 million during the quarter, compared to analyst estimates of $592.49 million. Vertex Pharmaceuticals had a net margin of 10.59% and a return on equity of 11.02%. The company’s revenue for the quarter was up 42.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.35 EPS. analysts predict that Vertex Pharmaceuticals Incorporated will post 1.63 earnings per share for the current year.

Vertex Pharmaceuticals declared that its Board of Directors has authorized a share buyback program on Wednesday, January 31st that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the pharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.

In related news, CEO Jeffrey M. Leiden sold 125,000 shares of the company’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $141.35, for a total value of $17,668,750.00. Following the completion of the transaction, the chief executive officer now directly owns 237,407 shares of the company’s stock, valued at approximately $33,557,479.45. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Paul M. Silva sold 1,289 shares of the company’s stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $152.31, for a total transaction of $196,327.59. Following the completion of the transaction, the senior vice president now directly owns 17,923 shares of the company’s stock, valued at $2,729,852.13. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 403,165 shares of company stock valued at $62,154,183. Company insiders own 1.80% of the company’s stock.

WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2018/02/09/mitsubishi-ufj-kokusai-asset-management-co-ltd-has-5-95-million-holdings-in-vertex-pharmaceuticals-incorporated-vrtx.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit